ROMA (ITALPRESS) – An investment of over 50 million euros to strengthen productive capacity, technological innovation and competitiveness, responding to the growing demand of the market in Italy and Europe. This is the message of Fine Foods Pharmaceuticals N.T.M. S.p.A., at the center of the new stage of “Fabbriche Aperte”, the project promoted by Egualia (association of the industries producing equivalent drugs, biosimilar and value added medicines in Italy) to enhance the role of companies engaged in the production of drugs in Italy, with a focus on those out of patents, opinion and public opinion.
The initiative has now staged in Brembate, in the production site of the company associated with Fine Foods & Pharmaceuticals N.T.M. S.p.A., an independent Italian CSDMO (Contract Solutions Development & Manufacturing Organization) specialized in the development and production on behalf of third parties of products for the nutraceutical, pharmaceutical and cosmetic industry and listed at the existing Euronext STAR Milan, where a new plant has been inaugurated. To open the works the landlord, the president of Fine Foods & Pharmaceuticals N.T.M. S.p.A., Marco Eigenmann.
Present at the cutting of the ribbon numerous representatives of the national and local institutions, including the president of Lombardy Region, Attilio Fontana, the president of the Finance Commission of the Senate, Massimo Garavaglia, the president of the Welfare Commission of Lombardy Region and member of the Board of Directors AIFA, Emanuele Monti, the mayor of Brembate, Luca Rosa, the vice mayor, Mario Doneda and the mayor of Verdellino, Silvano Zanoli. In connection Elena Lorenzini, Deputy Chief Cabinet of MIMIT.
“The inauguration of the new extension of the Brembate Pharmaceutical Production Site represents for Fine Foods much more than an industrial investment: it is the confirmation of the solidity of our business model and the long-term vision leading the Group. As an independent CSDMO, we place ourselves as a strategic partner for more than 130 global brands and for the entire supply of equivalent Italian drugs, providing advanced scientific skills, advanced production capabilities and an approach oriented to the transformation of complexity into concrete solutions for our customers. The new structure was born to accompany the Group’s future growth and further strengthen our international position”, commented Marco Eigenmann, president of Fine Foods.
“For ten years, “Aperte Factories” has shown concretely the industrial face of our supply chain through the structures, production processes and human resources of companies that produce equivalent medicines in Italy: companies that invest, innovate and produce in our country essential medicines for millions of citizens – said Riccardo Zagaria, president of Egualia – Today the equivalent drugs represent almost 40% of the medicines dispensed in Italy through pharmacies and hospitals and constitute a pharmaceutical component.
The value of the equivalent drug sector, however, can no longer be read only in terms of savings. The sector has almost 11 thousand direct employees, engaged in over 100 companies and 50 production plants that are entirely or partly dedicated to this component of the Italian pharmaceutical industry. An ecosystem that generates 6.4 billion euros of production, with at the center the supply chain of CMO and CDMO, 1.6 billion euros of direct added value and 2.2 billion euros of export. The global supply chain crisis, geopolitical tensions and the issue of security of supply have also highlighted the strategic role that patented medicinal products play for the Italian and European industrial system.
“Investiments like the one made by Fine Foods show that there is an advanced and advanced production capacity on which to build a real industrial policy for the drug. Europe and Italy must choose whether to continue to consider these medicines exclusively as a containment of expenditure or as a strategic infrastructure of public health, industrial resilience and productive autonomy. We need consistent policies that support investment, manufacturing capacity and security of supplies for millions of citizens, especially those most fragile affected by chronic diseases,” said President Zagaria.
“”Fabbriche Aperte” is an important occasion to show the strategic value of a sector that the government considers central to the industrial future of the country – said Adolfo Urso, Minister of Enterprises and Made in Italy, in the message sent on the occasion of the event – . With the permanent table on industrial and health policy, established at MIMIT together with Minister Schillaci, they would work to strengthen the national supply chain and ask Europe to introduce new constraints.
For the managing director, Pietro Oriani, “the production site of Brembate is today one of the most advanced references of the Italian pharmaceutical sector. At the existing site we have joined a new building of about 11,000 square meters, authorized by AIFA in October 2025 and already fully operational. Here technology, quality and sustainability coexist in an advanced production model that allows you to realize tablets and capsules managing numerous different active ingredients according to the highest safety and quality standards. The investment of more than 50 million euros is not only a new production capacity, but also an important employment development engine in Lombardy, where the Group concentrates, in the three establishments dedicated to the Nutraceutical, Pharmaceutical and Cosmetic Business Units, 148 production lines and almost 1,000 highly specialized employees and employees”.
– photo press Egualia –
(ITALPRESS).
